Peptide therapeutics for rare genetic metabolic diseases

Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Year Invested: 2010
Location: Boston, Mass.

Recent News

March 12, 2018
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

March 7, 2018
Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March

January 4, 2018
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

Read More News

Associated Team Members

Neil Exter